Head-To-Head Analysis: Rafael (RFL) and Its Rivals

Rafael (NYSE:RFL) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Rafael to similar companies based on the strength of its analyst recommendations, dividends, earnings, valuation, institutional ownership, profitability and risk.

Valuation & Earnings

This table compares Rafael and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rafael	$874,000.00	-$30.52 million	-1.89
Rafael Competitors	$4.46 billion	$3.17 billion	545.50

Rafael’s peers have higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Rafael and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1	0	0	0	1.00
Rafael Competitors	7759	13846	25693	1031	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 23.99%. Given Rafael’s peers stronger consensus rating and higher possible upside, analysts plainly believe Rafael has less favorable growth aspects than its peers.

Profitability

This table compares Rafael and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rafael	-3,390.73%	-39.52%	-33.73%
Rafael Competitors	-2,380.91%	-221.73%	-15.99%

Insider and Institutional Ownership

11.3% of Rafael shares are held by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 32.9% of Rafael shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Rafael has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Rafael’s peers have a beta of -4.29, suggesting that their average stock price is 529% less volatile than the S&P 500.

Summary

Rafael peers beat Rafael on 10 of the 13 factors compared.

About Rafael

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.